leisure time -WSS

leisure time

author：hotspot 2025-09-03 14:43:10 - browse：2

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： ‘Oppenheimer’ and the risks of AI in health care

WSS

Updated Covid vaccine has 54% effectiveness, new study suggests

The CDC's new social media misinformation war

The CDC's new social media misinformation war

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

A protest over insulin prices is seen as a fight for life

Scientists inch closer to single

hotspot

leisure time

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Trump indictment: Who are the 'co

Jerome Adams on the need for new antivirals for Covid

The high personal cost of affirmative action for Black doctors

Anesthesiologist group: stop taking Ozempic before surgery

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Peter Hotez and the public health issue of online harassment

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Walensky prepares to leave CDC — and Congress — behind

EQRx, failed developer of low

focus

A single Democrat is willing to weaken Medicare negotiation power

Problems with a popular proposal to regulate AI in health care

Why Novartis is going to walk from its acquisition of MorphoSys

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Trump indictment: Who are the 'co

entertainment

focus

Wikipedia

hotspot